GE HealthCare Technologies Inc. GEHC
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, GE HealthCare Technologies Inc. gets an algorithmic score of 49/100. It trades at 66.46 $, with a bearish technical trend (RSI 46.3) and 34.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.63): defensive profile.
- Meaningful dividend (24.00%).
Weaknesses
- —
Fundamentals
| P/E | 15.38 |
| Forward P/E | 12.28 |
| PEG | 1.65 |
| P/B | 2.74 |
| EV/EBITDA | 10.78 |
| P/S | 1.42 |
| ROE % | 19.38 |
| ROA % | 5.13 |
| Gross margin % | 39.53 |
| Operating margin % | 14.98 |
| Net margin % | 9.33 |
| Revenue growth % (y/y) | 5.80 |
| Earnings growth % (y/y) | 16.80 |
| Revenue CAGR % | 3.99 |
| Earnings CAGR % | 2.84 |
| Debt/Equity % | 93.97 |
| Current ratio | 1.26 |
| FCF yield % | 4.98 |
| Dividend yield % | 24.00 |
| Payout % | 3.23 |
Returns
| 1 month | -7.3 % |
| 3 months | +3.9 % |
| 6 months | -3.3 % |
| YTD | -19.6 % |
| 1 year | -8.1 % |
| 3 years | +3.9 % |
Risk
| 1-year volatility | 34.5 % |
| Beta | 0.63 |
| 5-year max drawdown | -37.4 % |
| Sharpe 1A | -0.19 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.